🇺🇸 KAD-1229 in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Adenocarcinoma — 1 report (10%)
2. Benign Prostatic Hyperplasia — 1 report (10%)
3. Bladder Cancer — 1 report (10%)
4. Cataract — 1 report (10%)
5. Colonic Stenosis — 1 report (10%)
6. Condition Aggravated — 1 report (10%)
7. Diabetic Retinopathy — 1 report (10%)
8. Large Intestine Carcinoma — 1 report (10%)
9. Metastases To Lymph Nodes — 1 report (10%)
10. Visual Acuity Reduced — 1 report (10%)

Source database →

Frequently asked questions

Is KAD-1229 approved in United States?

KAD-1229 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for KAD-1229 in United States?

Kissei Pharmaceutical Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.